ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,389Medicare Part D Prescriptions Filled, Including Refills

Rank: 597 out of 5176

$550K Total Retail Price of All Prescriptions

Rank: 957 out of 5176

262 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 262 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 9,691 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

40 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 596 567 1 1
AMLODIPINE BESYLATE 506 464 2 2
FUROSEMIDE 456 429 3 8
METOPROLOL TARTRATE 310 285 4 6
OMEPRAZOLE 295 288 5 3
ENALAPRIL MALEATE 278 259 6 22
METOPROLOL SUCCINATE 267 246 7 11
LISINOPRIL 263 251 8 5
FAMOTIDINE 199 175 9 58
DONEPEZIL HCL 197 197 10 28
NAMENDA 185 185 11 47
NEXIUM 180 180 12 16
METFORMIN HCL 152 135 13 7
LEVOTHYROXINE SODIUM 147 126 14 4
CRESTOR 142 142 15 15
ZOLPIDEM TARTRATE 141 126 16 17
DIOVAN 140 140 17 19
HYDROCHLOROTHIAZIDE 126 118 18 10
ATENOLOL 125 122 19 12
CARVEDILOL 121 120 20 24
QUETIAPINE FUMARATE 120 120 21 75
WARFARIN SODIUM 116 107 22 13
PLAVIX 114 108 23 29
RISPERIDONE 108 108 24 78
CLOPIDOGREL 101 101 25 26
LOSARTAN POTASSIUM 98 92 26 14
ISOSORBIDE MONONITRATE ER 95 95 27 44
NYSTATIN-TRIAMCINOLONE 95 88 27 142
SEROQUEL 95 95 27 166
IBUPROFEN 90 71 30 72
LEVETIRACETAM 85 80 31 92
GABAPENTIN 84 73 32 21
ATORVASTATIN CALCIUM 84 84 32 9
ADVAIR DISKUS 83 73 34 32
RAMIPRIL 79 78 35 50
JANUVIA 75 75 36 25
NAPROXEN 73 50 37 95
LACTULOSE 73 71 37 87
TRAMADOL HCL 71 71 39 40
HYDRALAZINE HCL 71 71 39 73
PRANDIN 65 65 41 150
MECLIZINE HCL 64 59 42 81
PHENYTOIN SODIUM EXTENDED 64 59 42 232
MIRTAZAPINE 63 63 44 45
DIGOXIN 63 63 44 56
CLONIDINE HCL 54 42 46 79
AZITHROMYCIN 52 50 47 42
GLIPIZIDE XL 52 52 47 83
AMMONIUM LACTATE 52 52 47 91
ALENDRONATE SODIUM 52 52 47 18
LANTUS SOLOSTAR 51 51 51 70
PROAIR HFA 51 51 51 60
METFORMIN HCL ER 50 50 53 57
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.